drugset / Trial / NCT00002572
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
Phase 1
Completed
10 enrolled
University of Colorado, Denver
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective treatment for recurrent brain tumors. PURPOSE: Phase I trial to study the effectiveness of cytotoxic T cells and interleukin-2 in treating adults with recurrent brain tumors.
Timeline
- Start
- 1994-11
- Primary completion
- 1999-12
- Completion
- 1999-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | Other |
| Subject | aldesleukin | Protein / enzyme biologic | — | Intrathecal |
| Background | muromonab-CD3 | Monoclonal antibody | — | — |